



Advances in Pathogenesis and Therapeutics of Hepatobiliary Diseases

Guest Editor:

Dr. Jinghua Wang

Institute of Oriental Medicine,
Dongguk University, 32,
Dongguk-ro, Goyang 10326,
Gyeonggi-do, Republic of Korea

Deadline for manuscript
submissions:

closed (28 February 2023)

Message from the Guest Editor

In mammals, the hepatic and biliary system comprises several essential organs, including the liver and bile duct, for participating in the metabolism of both diets and drugs. In recent decades, the burden of hepatobiliary disease has been heavy, and the overall trend is gradually upwards worldwide. Recently, with the rapid improvement of cutting-edge technology, for instance, gut-microbiota-derived PAMPs (pathogen-associated molecular patterns) and bile acid metabolites affect liver cancer progression and metastasis through immune-regulation. Further, many studies have shown that commensal microbes play a crucial role in non-alcoholic fatty liver disease. However, the causality and corresponding mechanisms are still indistinct. Therefore, this Special Issue, titled “Advances in Pathogenesis and Therapeutics of Hepatobiliary Diseases”, welcomes the submission of original research and review articles to address hepatobiliary disorders concerning novel insights into pathogenesis and therapeutic strategies. We look forward to your contributions.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI